In my opinion no capital raising is to be expected. Their debt levels are a bit high especially with the new debt from SOL but it should be considered manageable at the present moment. Profits should be OK to cover debt and interest.
"Expectations of a modest Operating EBITDA profit for 1H2019 compared to an Operating EBITDA loss of $1.8 million for the prior corresponding period despite the incurrence of non‐recurring legal expenses and an increased investment in research and development."
Last year result was a loss around 5 million.
- Forums
- ASX - By Stock
- News: PAL Palla Pharma Enters Into New Multi‐Year Supply Agreement With A European Customer
In my opinion no capital raising is to be expected. Their debt...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)